http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Cornea/Article/list/417 Cornea disease states including allergic conjunctivitis, corneal edema, as well as corneal ulcers/lesions, keratitis sicca/dry eye, keratitis/inflammation, and keratoconus. Treatments such as corneal transplants and radial keratotomy (RK). 2009-11-21T16:24:30Z http://www.modernmedicine.com/modernmedicine/Cornea+News/Eye-and-cornea-research-made-easier-by-two-antibod/ArticleStandard/Article/detail/571959?contextCategoryId=417&ref=25 A global biotechnology company focused in inflammation and neurology research, announced the launch of two monoclonal antibodies (Lumican and Keratocan, MD Biosciences). 2008-12-16T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/512008/571959null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/FDA-approves-Sirions-NDA-for-ganciclovir-015-for-h/ArticleStandard/Article/detail/631228?contextCategoryId=417&ref=25 The FDA has approved a new drug application (NDA) for ganciclovir ophthalmic gel 0.15% (Zirgan, Sirion Therapeutics) as a treatment for acute herpetic keratitis (dendritic ulcers), the company announced. 2009-10-02T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412009/631228null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/DSEK-shown-to-be-safe-effective-therapy-according-/ArticleStandard/Article/detail/624925?contextCategoryId=417&ref=25 Descemet's stripping endothelial Keratoplasty (DSEK) was shown to be a safe and effective treatment for corneal endothelial diseases, according to a 2009 review by the cornea panel of the American Academy of Ophthalmology's (AAO) Ophthalmic Technology Assessment Committee, led by W. Barry Lee, MD. 2009-09-08T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/372009/624925null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Study-Sodium-hyaluronate-solution-safe-effective/ArticleStandard/Article/detail/627671?contextCategoryId=417&ref=25 An investigational compound for the treatment of dry eye disease consisting of a proprietary formulation of sodium hyaluronate ophthalmic solution 0.18% (Vismed, Lantibio Inc.) was shown to be safe and effective in a multicenter phase III trial conducted in the United States. A new drug application has been filed for the solution, which is already marketed in parts of Europe and Asia as a viscoelastic lubricant eye drop. 2009-09-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/382009/627671null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Low-IOP-is-measured-with-great-accuracy-using-non-/ArticleStandard/Article/detail/617069?contextCategoryId=417&ref=25 A non-contact applanation tonometer (Ocular Response Analyzer, Reichert) appears to be more effective than the Goldmann applanation tonometer (GAT) in assessing very low and negative IOP values using the non-contact applanation tonometer's corneal-compensated IOP (IOPcc) parameter. The GAT may be the long-accepted gold standard, but the more accurate assessment of IOP using the non-contact applanation tonometer challenges this gold standard and raises questions as to which of the two techniques is optimal in measuring IOP. 2009-08-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/322009/617069null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Osmometer-comparison-shows-newer-technology-allows/ArticleStandard/Article/detail/610893?contextCategoryId=417&ref=25 A head-to-head comparison of an older nanoliter osmometer (Clifton Technical Physics) and a newer osmometer (OcuSense) shows that both devices are effective in measuring tear osmolarity and produce comparable measurements. The newer device has great potential for office clinical use, because readings can be taken very easily and quickly by a non-trained individual, according to one doctor. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610893null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Intraductal-meibomian-gland-probing-reduces-inflam/ArticleStandard/Article/detail/610890?contextCategoryId=417&ref=25 A new technique of intraductal meibomian gland probing using disposable cannulas of various lengths appears highly effective in providing quick and lasting relief from inflammatory symptoms of obstructive meibomian gland disease. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610890null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Epinastine-HCl-shows-utility-in-dry-eye-allergy/ArticleStandard/Article/detail/610895?contextCategoryId=417&ref=25 Dry eye disease is a common concomitant finding in patients with allergic conjunctivitis. Treatment selection can be challenging because some anti-allergy agents with antihistaminic activity can cause ocular surface drying. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610895null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Industry+News/Dr-Alfonso-named-chairman-at-Bascom-Palmer/ArticleStandard/Article/detail/610826?contextCategoryId=417&ref=25 Eduardo C. Alfonso, MD, has been named chairman of the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, according to a prepared statement. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610826null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Eye-drop-formulation-found-effective-for-post-LASI/ArticleStandard/Article/detail/610897?contextCategoryId=417&ref=25 Optive Sensitive (Allergan) was safe and effective for the management of dry eye signs and symptoms after LASIK surgery and may have some incremental benefits over standard tear management. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610897null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Artificial-tear-product-improves-functional-visual/ArticleStandard/Article/detail/610896?contextCategoryId=417&ref=25 An evaluation of functional visual performance of two currently marketed artificial tear products using the interblink interval visual acuity decay method showed that a tear with a polyethylene glycol/propylene glycol (PEG/PG)-based formulation (Systane Ultra, Alcon Laboratories) resulted in a statistically significant increase in the length of time within one line of best-corrected visual acuity (BCVA) within an interblink period at 90 minutes after instillation of a single drop. The drop was compared with a carboxymethylcellulose/glycerin-based tear (Optive, Allergan). Median times to one-line loss of BCVA were not statistically different at the timepoints of 15 or 45 minutes post-instillation. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610896null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Allergic-conjunctivitis-efficacy-of-olopatadine-02/ArticleStandard/Article/detail/610894?contextCategoryId=417&ref=25 Olopatadine hydrochloride 0.2% ophthalmic solution (Pataday, Alcon Laboratories), an antihistamine/mast cell stabilizer, is highly effective for treating allergic conjunctivitis, according to two clinicians who spoke with Ophthalmology Times. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610894null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/PostLASIK-dry-eye-treatment-using-sodium-hyalurona/ArticleStandard/Article/detail/610904?contextCategoryId=417&ref=25 The benefits of two artificial tear products were compared in a head-to-head, randomized, contralateral eye-controlled study enrolling 40 patients undergoing bilateral LASIK. Wavefront analysis was used for the primary outcome assessment of quality of vision and favored use of a sodium hyaluronate-based product (Blink Tears, Abbott Medical Optics). 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610904null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Lid-wiper-epitheliopathy-Oil-in-water-emulsion-mai/ArticleStandard/Article/detail/610906?contextCategoryId=417&ref=25 An oil-in-water emulsion and a corticosteroid both were effective in eliminating the signs and symptoms of lid wiper epitheliopathy after a 1-month active treatment phase in a recent study. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610906null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/When-using-punctal-plugs-for-dry-eye-surgeon-favor/ArticleStandard/Article/detail/610889?contextCategoryId=417&ref=25 When faced with a decision about which type of punctal plug to use in the management of dry eye, one oculofacial plastic surgeon said she turns to traditional occluders made of silicone because they have a long track record and are easily visualized for removal, if necessary. She has not used intracanalicular plugs made of polyglycolic acid or hydrogel but said they seem promising. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610889null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Patients-with-dry-eye-find-symptom-relief-quality-/ArticleStandard/Article/detail/610903?contextCategoryId=417&ref=25 Use of a proprietary hydroxypropyl cellulose ophthalmic insert (Lacrisert, Aton Pharma) in patients with dry eye syndrome can improve dry eye symptoms and significantly improve the quality of life for these patients, according to a recent study. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610903null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Dry-eye-progression-prevented-by-cyclosporine/ArticleStandard/Article/detail/610891?contextCategoryId=417&ref=25 A recent study showed that moderate to severe dry eye disease can be best treated with anti-inflammatory medications such as topical cyclosporine. According to one ophthalmologist, cyclosporine can significantly limit progression of dry eye disease and should be considered a "go-to" therapy in this patient population. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610891null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Post-LASIK-healing-rate-may-be-increased-by-hyprom/ArticleStandard/Article/detail/610905?contextCategoryId=417&ref=25 Hypromellose 0.3% gel (GenTeal Gel, Novartis Ophthalmics) may increase the rate of re-epithelialization of the gutter around LASIK flaps during the first postoperative week. 2009-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292009/610905null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Cornea/Bascom-Palmer-names-Eduardo-C-Alfonso-MD-its-new-c/ArticleStandard/Article/detail/608859?contextCategoryId=417&ref=25 Eduardo C. Alfonso, MD, is the new chairman of the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine. Dr. Alfonso is the fifth chairman to be named in the institute's 47-year history. 2009-07-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/282009/608859null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Corneal-edema-patients-at-higher-risk-for-transpla/ArticleStandard/Article/detail/601688?contextCategoryId=417&ref=25 The corneal transplant failure rate was four times higher in patients diagnosed with corneal edema associated with either IOL implants or no natural lens following cataract removal, than in patients diagnosed with Fuchs' dystrophy, according to a study. 2009-06-04T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/232009/601688null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Inspire-initiates-phase-II-trials-with-azithr/ArticleStandard/Article/detail/596780?contextCategoryId=417&ref=25 Inspire Pharmaceuticals Inc. announced it has initiated two phase II clinical trials with azithromycin ophthalmic solution 1% (AzaSite) to pursue a potential indication for the treatment of blepharitis. The drug currently is approved by the FDA for the treatment of bacterial conjunctivitis. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596780null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/Cyclosporine-for-dry-eye-shows-significant-improve/ArticleStandard/Article/detail/596113?contextCategoryId=417&ref=25 Phase II of a clinical study examining a formulation of cyclosporine (Cyclokat, Novagali Pharma) has been completed, and results demonstrate statistically significant improvement with signs and symptoms in patients suffering from moderate-to-severe dry eye syndrome. 2009-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/182009/596113null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Tonometry-measurements-characterize-changes-in-ker/ArticleStandard/Article/detail/597247?contextCategoryId=417&ref=25 Results of a study using a non-contact applanation tonometer (Ocular Response Analyzer, Reichert) to evaluate keratoconic eyes during and after corneal collagen crosslinking demonstrate changes in tonometer measurements that are consistent with changes in corneal thickness, hydration, and regularity. 2009-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/597247null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Modern+Medicine+Now/Donor-death-surgery-interval-may-affect-DSAEK-outc/ArticleStandard/Article/detail/597244?contextCategoryId=417&ref=25 Data analyzed from a total of 568 eyes included in a prospective study of Descemet's stripping automated endothelial keratoplasty indicate that the time from donor death to surgery affects endothelial cell density loss and risk of graft dislocation, but more data are needed to understand possible associations better. 2009-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/597244null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ASCRS-Scheimpflug-device-ultrasound-pachymetry-bot/ArticleStandard/Article/detail/591753?contextCategoryId=417&ref=25 San Francisco—Both ultrasound pachymetry and a proprietary Scheimpflug imaging device (Galilei Dual Scheimpflug Analyzer, Ziemer Ophthalmic Systems) produced excellent repeatability of central corneal thickness (CCT) measurements, and the repeatability was strong for both "virgin" and post-refractive eyes, according to Mitchell P. Weikert, MD, MS, assistant professor of ophthalmology, Baylor College of Medicine, Houston. 2009-04-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152009/591753null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ASCRS-Novel-pachymetric-map-analysis-detects-kerat/ArticleStandard/Article/detail/591754?contextCategoryId=417&ref=25 San Francisco—Gaussian fitting on inverse normalized pachymetry maps enables quantification of the depth and width of focal thinning associated with keratoconus and is showing promise as a new method for diagnosing this corneal ectatic disease, said David Huang, MD, PhD, of the University of Southern California, Los Angeles. 2009-04-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152009/591754null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ASCRS-Air-bubble-injection-may-be-a-source-of-endo/ArticleStandard/Article/detail/591749?contextCategoryId=417&ref=25 San Francisco—Results of a study using an ex vivo model suggest a possible role for air bubble-induced trauma in loss of endothelial cell density after Descemet's stripping automated endothelial keratoplasty (DSAEK), said Anna Hong, MD, a resident at the Duke University Eye Center, Durham, NC. 2009-04-05T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152009/591749null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ASCRS-Efficacy-safety-data-support-recommendation-/ArticleStandard/Article/detail/591526?contextCategoryId=417&ref=25 San Francisco—In eyes with normal endothelium requiring corneal transplantation, deep anterior lamellar keratoplasty (DALK) using Anwar's big-bubble technique can result in visual acuity outcomes that are at least as good as those experienced after penetrating keratoplasty (PKP) and with the advantage of causing fewer complications than the full thickness procedure, said Donald H. Tan, MD, deputy director and head, corneal service, Singapore National Eye Centre, and head and professor of ophthalmology, National University of Singapore. 2009-04-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/591526null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ASCRS-Multiple-routes-of-administration-viable-for/ArticleStandard/Article/detail/591529?contextCategoryId=417&ref=25 San Francisco—Although the debate continues regarding the pros and cons of different approaches to antibiotic prophylaxis for postoperative endophthalmitis, available data are clear in demonstrating that it is critical to assure an effective concentration is present at the time of surgery and maintained in the early postoperative period, said Randall J. Olson, MD, John A. Moran Presidential Professor and chairman of the Department of Ophthalmology and Visual Sciences, University of Utah School of Medicine, Salt Lake City. 2009-04-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/591529null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ASCRS-Femtosecond-laser-enables-PKP-but-not-all-ey/ArticleStandard/Article/detail/591527?contextCategoryId=417&ref=25 San Francisco—Femtosecond laser-assisted penetrating keratoplasty (PKP) has potential advantages over conventional PKP performed with manual corneal trephination. 2009-04-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/591527null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ASCRS-FDA-trial-data-positive-for-corneal-collagen/ArticleStandard/Article/detail/591528?contextCategoryId=417&ref=25 San Francisco—An interim analysis of data from an ongoing U.S. clinical trial shows corneal collagen crosslinking using riboflavin and ultraviolet A (UVA) light has promising efficacy and safety for the treatment of progressive keratoconus and postLASIK ectasia, said R. Doyle Stulting, MD, PhD, professor of ophthalmology, Emory University, Atlanta. 2009-04-03T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142009/591528null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/For-dry-eye-patients-punctal-plugs-offer-flow-cont/ArticleStandard/Article/detail/585651?contextCategoryId=417&ref=25 Soft Plug Flow Control Silicone Plugs (Oasis Medical) provide partial occlusion of the puncta with limited tear drainage for patients with moderate and severe dry eye. These plugs eliminate epiphora in patients for whom total occlusion is excessive. 2009-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/102009/585651null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Corneal-topography-stability-after-crosslinking-is/ArticleStandard/Article/detail/585650?contextCategoryId=417&ref=25 Results from visual acuity testing, refraction, and corneal topography analysis using Scheimpflug imaging (Pentacam, Oculus) in a series of 48 eyes with progressive keratoconus demonstrate the benefits of corneal collagen crosslinking for halting keratoconus progression. More research is needed to provide answers to questions about the long-term stability of collagen corneal crosslinking and to refine its indications and contraindications. 2009-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/102009/585650null XML http://www.modernmedicine.com/modernmedicine/Cornea/Tear-formulations-unique-in-dry-eye-therapy-manage/ArticleStandard/Article/detail/582510?contextCategoryId=417&ref=25 Blink GelTears and Blink Tears Preservative-Free (Advanced Medical Optics) are two new over-the-counter products for the treatment of dry eye disease. These products are gaining in popularity with ophthalmologist because of the rapid long-lasting beneficial response they produce in this patient population and the absence of a preservative. The products are also beneficial for patients who have undergone LASIK and cataract surgery and develop subsequent dry eye signs and symptoms postoperatively. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582510null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Dry-eye-treatment-should-be-tailored-to-patient/ArticleStandard/Article/detail/582492?contextCategoryId=417&ref=25 Dry eye is a chronic disease that requires adjustments to treatment, follow-up, re-testing, monitoring of progress, and changes of medication. Treatment should be tailored for each patient. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582492null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Lipid-emulsion-benefits-dry-eye-disease-says-docto/ArticleStandard/Article/detail/582500?contextCategoryId=417&ref=25 A compromised lipid layer plays a key role in the development and perpetuation of dry eye disease because it allows increased aqueous evaporation and fails to protect against friction between the blinking lid and the ocular surface. A proprietary brand of emollient eye drops (Soothe XP. Bausch & Lomb) was created to re-establish the tear film lipid layer and restore moisture, and it is an effective choice for providing symptomatic relief in patients with dry eye disease, says one optometrist. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582500null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Dry-eye-drops-and-the-different-implications-for-p/ArticleStandard/Article/detail/582490?contextCategoryId=417&ref=25 Important differences exist between the various classes of over-the-counter eye drops. Physicians play a vital role in explaining these differences, as well as their potential implications in the treatment of the symptoms of dry eye and other conditions, to patients. Educating patients about the available formulations not only may expedite the relief of their symptoms but also may save them time and money. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582490null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Dry-eye-and-allergy-clues-are-right-before-your-ey/ArticleStandard/Article/detail/582496?contextCategoryId=417&ref=25 A careful look at all the clues can help the clinician differentiate between dry eye and allergies. The patient history may contain the most important clues for establishing a diagnosis. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582496null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Dry-eye-in-patients-undergoing-LASIK-requires-proa/ArticleStandard/Article/detail/582495?contextCategoryId=417&ref=25 Recognizing and treating dry eye disease before LASIK is an important strategy for mitigating patient unhappiness after surgery. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582495null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Eye-drops-for-contact-lens-wearers-are-found-to-be/ArticleStandard/Article/detail/582498?contextCategoryId=417&ref=25 A clinical trial tested the safety and efficacy of Optive eye drops (Allergan) in contact lens wearers. Participants reported no adverse events and that their lenses were more comfortable to wear; clinical assessment found no adverse events or complications after 4 weeks of treatment. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582498null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Dry-eye-common-postLASIK----and-before/ArticleStandard/Article/detail/582499?contextCategoryId=417&ref=25 A review of the world literature shows that about one-third of patients who are undergoing LASIK already suffer from dry eye, and the proportion affected after surgery is similar. In most cases, however, dry eye does not appear to affect postoperative vision and satisfaction outcomes adversely. Identification of patients at risk and pre-treating may reduce the postoperative incidence of dry eye. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582499null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Anti-allergy-drop-does-not-cause-dryness-to-ocular/ArticleStandard/Article/detail/582493?contextCategoryId=417&ref=25 A novel ophthalmic anti-allergy agent, epinastine HCl ophthalmic solution 0.05% (Elestat, Inspire Pharmaceuticals), effectively controls ocular allergy in patients with dry eye, according to Jodi Luchs, MD, FACS. The drop has been shown to rapidly prevent ocular allergy symptoms by blocking H1 and H2 receptors, stabilizing mast cells, and inhibiting the release of proinflammatory mediators. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582493null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Meibomian-gland-disease-therapy-eased-by-kit/ArticleStandard/Article/detail/582494?contextCategoryId=417&ref=25 A new product (NutriDox Convenience Kit, Advanced Vision Research) is designed to make the treatment of meibomitis, posterior blepharitis, and meibomian gland disease more convenient for patients and clinicians. The prescription-only system includes an antibiotic, nutrition therapy, and a lid-cleansing component. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582494null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Bepotastine-is-effective-against-allergic-conjunct/ArticleStandard/Article/detail/582491?contextCategoryId=417&ref=25 Bepotastine besilate 1.0% (Bepreve, ISTA Pharmaceuticals), an ocular allergy compound under new drug application review by the FDA, is effective in reducing ocular itching associated with allergic conjunctivitis and also seems to improve other allergy symptoms. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582491null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Ophthalmologists-perception-of-moderate-to-severe-/ArticleStandard/Article/detail/582501?contextCategoryId=417&ref=25 Ophthalmologists who responded to questions about treatment of dry eye indicated that there are limitations in the available treatment options, especially for patients with moderate to severe cases of the disease, and that only 5% of ophthalmologists saw existing treatments as effective for the patients with the worst cases. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582501null XML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Ecabet-shows-promise-for-dry-eye-in-phase-IIb-stud/ArticleStandard/Article/detail/582497?contextCategoryId=417&ref=25 Ecabet sodium (ISTA Pharmaceuticals), an anti-ulcer and gastritis drug under development for the treatment of dry eye, showed positive results in a phase IIb clinical trial of the drug. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582497null XML http://www.modernmedicine.com/modernmedicine/Ophthalmology/Tear-film-rebuilding-is-goal-of-drop/ArticleStandard/Article/detail/582511?contextCategoryId=417&ref=25 A new formulation of lubricant eye drop (Systane Ultra, Alcon Laboratories) contains polymer network and demulcent ingredients that have been proven in multiple studies to provide benefits in patients with dry eye disease, according to one ophthalmologist. The drop, however, reformulates these agents in a system designed to further enhance ocular surface comfort, protection, and symptomatic relief. Initial patient impressions are very positive, he said. 2009-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082009/582511null XML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ISTA-announces-results-of-phase-IIb-study-of-ecabe/ArticleStandard/Article/detail/579948?contextCategoryId=417&ref=25 Patients treated with ecabet sodium demonstrated a strong positive trend in the objective sign of tear film break-up time and a positive trend in the objective sign of quantity of tears produced in a phase IIb study conducted by ISTA Pharmaceuticals. 2009-02-05T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/062009/579948null HTML http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Resident-Writers-Award-Femtosecond-laser-assisted-/ArticleStandard/Article/detail/577636?contextCategoryId=417&ref=25 The femtosecond laser may be useful in the treatment of advanced fungal keratitis, according to this case presentation. 2009-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052009/577636null XML http://www.modernmedicine.com/modernmedicine/Cornea+Feature/Intracameral-triamcinolone-may-be-viable-PKP-treat/ArticleStandard/Article/detail/560435?contextCategoryId=417&ref=25 Topical, periocular, and/or systemic corticosteroids typically are used to treat corneal endothelial graft rejection. When those modalities fail, experience in a series of five eyes suggests intracameral triamcinolone acetonide may be worth considering. 2008-11-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/432008/560435null XML http://www.modernmedicine.com/modernmedicine/Cornea+Feature/Dry-eye-a-serious-public-health-problem/ArticleStandard/Article/detail/559861?contextCategoryId=417&ref=25 Considerable progress has been made in recent years in the understanding of the epidemiology of dry eye disease. Here, two doctors discuss some of the studies that have helped ophthalmologists understand the prevalence, burden, and risk factors of dry eye disease. They also highlight how improved diagnosis will have a significant effect on the quality of life of patients with dry eye. 2008-10-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/432008/559861null XML http://www.modernmedicine.com/modernmedicine/Cornea+Feature/Artificial-cornea-useful-in-patients-with-multiple/ArticleStandard/Article/detail/556874?contextCategoryId=417&ref=25 In patients who have suffered multiple immunologic graft rejections, the chance of providing good-quality vision is dramatically increased with a keratoprosthesis than another transplant. Patients who receive a keratoprosthesis have rapid visual return, a good quality of vision, and a high rate of graft survival. 2008-10-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/412008/556874null XML http://www.modernmedicine.com/modernmedicine/Cataract/Prepare-for-hyperopic-shift-following-DSAEK-graft-/ArticleStandard/Article/detail/553278?contextCategoryId=417&ref=25 A retrospective study including 45 eyes that underwent Descemet's stripping automated endothelial keratoplasty (DSAEK) found an average refractive change of +0.88 D after surgery. That hyperopic shift after DSAEK has implications for management of patients undergoing cataract surgery simultaneously with or after DSAEK and for anticipating refractive outcomes in pseudophakic patients undergoing DSAEK. 2008-10-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/392008/553278null HTML http://www.modernmedicine.com/modernmedicine/General+Ophthalmology+Feature/Instrument-analyzes-biomechanical-function-of-tiss/ArticleStandard/Article/detail/544819?contextCategoryId=417&ref=25 Proprietary instrumentation (Ocular Response Analyzer, Reichert Ophthalmic Instruments) is useful in ophthalmology, but the current generation of the instrument may have some limitations, according to one physician. 2008-08-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/352008/544819null XML http://www.modernmedicine.com/modernmedicine/Cornea+Feature/Optical-coherence-tomography-a-useful-addition-to-/ArticleStandard/Article/detail/544820?contextCategoryId=417&ref=25 A proprietary device for optical coherence tomography (Visante, Carl Zeiss Meditec) seems to be a highly useful addition to clinical practice. The instrument, according to one physician, may be the best resource thus far to evaluate placement of intracorneal segments, femtosecond laser-enabled keratoplasty, and penetrating keratoplasty. 2008-08-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/352008/544820null XML http://www.modernmedicine.com/modernmedicine/Cornea/Vaccines-may-have-future-in-ocular-HZV-and-HPV/ArticleStandard/Article/detail/543117?contextCategoryId=417&ref=25 Vaccines may have a role in corneal and external ocular disease, specifically for herpes zoster virus and human papilloma virus infections, because of the successes of the vaccines in preventing systemic diseases. 2008-08-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/342008/543117null HTML http://www.modernmedicine.com/modernmedicine/Cornea+Feature/Riboflavin-and-UV-treatment-promotes-collagen-cros/ArticleStandard/Article/detail/544831?contextCategoryId=417&ref=25 The combination of ultraviolet radiation and riboflavin treatment to achieve collagen cross-linking may be beneficial in biomechanical stabilization of ectasia, according to an expert who says the combined procedure has reduced the need for penetrating keratoplasty in his practice by 70%. 2008-08-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/352008/544831null XML http://www.modernmedicine.com/modernmedicine/Dry+Eye/Topical-cyclosporine-helps-prevent-dry-eye-progres/ArticleStandard/Article/detail/530333?contextCategoryId=417&ref=25 Topical cyclosporine 0.05% (Restasis, Allergan) limited progression or improved dry eye severity levels in most patients, while the use of artificial tears alone led to worsening of disease severity levels in nearly one-third of patients in a 12-month randomized study. The rapid progression of the disease in patients using artificial tears and the improvements in the patients using cyclosporine suggest that medication use could be beneficial for many individuals with level 2 dry eye disease. 2008-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292008/530333null XML http://www.modernmedicine.com/modernmedicine/Dry+Eye/Assessment-of-antimuscarinic-activity-of-topical-a/ArticleStandard/Article/detail/530341?contextCategoryId=417&ref=25 Out of seven anti-allergy medications examined in a laboratory study epinastine is a potent antihistamine but has minimal anticholingeric activity. Ideally, allergy medication should effectively target the histamine receptors without causing adverse effects such as ocular dryness. 2008-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292008/530341null XML http://www.modernmedicine.com/modernmedicine/Dry+Eye/Oral-treatment-options-abound-for-dry-eye/ArticleStandard/Article/detail/530330?contextCategoryId=417&ref=25 The eyes can be affected by over-the-counter (OTC) systemic medications, nutrition habits, and systemic agents—all of which contribute to dry eye. Oral treatment options should be considered in these cases, whereas topical treatment with artificial tears is the best option for external causes. 2008-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292008/530330null XML http://www.modernmedicine.com/modernmedicine/Dry+Eye/Newer-punctal-plug-designs-aim-to-provide-longer-t/ArticleStandard/Article/detail/530331?contextCategoryId=417&ref=25 By implanting a punctal plug in both the superior and inferior punta—literally, plugging the drains—clinicians can reduce tear turnover rate via these ducts. Reducing nasolacrimal drainage is one way of increasing tear volume on the ocular surface, in the hopes of prolonging the residence time of the tear film, and thus improving the signs and symptoms of dry eye. 2008-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292008/530331null XML http://www.modernmedicine.com/modernmedicine/Dry+Eye/Dry-eye-disease-have-we-found-the-perfect-diagnost/ArticleStandard/Article/detail/530338?contextCategoryId=417&ref=25 Tear hyperosmolarity is central to the dry eye disease process and the value of measuring tear osmolarity in the diagnosis of dry eye disease is well established. Alan Tomlinson, PhD, DSc, FCOptom, and Michael A. Lemp, MD, discuss the obstacles that physicians have come up against when attempting to diagnose dry eye effectively and accurately in a clinic setting. They also report on the latest research that has yielded some effective and user-friendly instruments, which now make osmolarity testing, and therefore, dry eye diagnosis, much easier. 2008-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292008/530338null XML http://www.modernmedicine.com/modernmedicine/Dry+Eye/Artificial-tear-delivers-high-performance-dry-eye-/ArticleStandard/Article/detail/530337?contextCategoryId=417&ref=25 A new high-performance artificial tear product (Systane Ultra, Alcon Laboratories) was created with an intelligent delivery system designed to maximize comfort upon instillation and provide sustained symptomatic relief and ocular surface protection. 2008-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292008/530337null XML http://www.modernmedicine.com/modernmedicine/Dry+Eye/Eyelid-cleanser-can-reduce-bacterial-colonization/ArticleStandard/Article/detail/530335?contextCategoryId=417&ref=25 An antimicrobial eyelid cleanser (SteriLid, Advanced Vision Research) reduces bacterial colonization in dry eye and blepharitis. The cleanser's active ingredient is linalool, a naturally occurring oil effective against a number of organisms. 2008-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292008/530335null XML http://www.modernmedicine.com/modernmedicine/Dry+Eye/New-OTC-drop-offers-dry-eye-relief-with-low-incide/ArticleStandard/Article/detail/530332?contextCategoryId=417&ref=25 A new artificial tear eye drop caused significantly less blurring on instillation than a control drop, and offers another option for the treatment of mild-to-moderate dry eye disease. 2008-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292008/530332null XML http://www.modernmedicine.com/modernmedicine/Dry+Eye/Unique-emulsion-eye-drop-restores-lipid-layer/ArticleStandard/Article/detail/530339?contextCategoryId=417&ref=25 New lubricant eye drops (Soothe XP Emollient Eye Drops, Bausch & Lomb) were specifically formulated to address lipid deficiency in the tear film, which is a critical factor in most patients with dry eye disease. 2008-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292008/530339null XML http://www.modernmedicine.com/modernmedicine/Dry+Eye/New-artificial-tear-benefits-patients-with-dry-eye/ArticleStandard/Article/detail/530334?contextCategoryId=417&ref=25 A product containing carboxymethylcellulose, glycerin, and a preservative (Optive, Allergan), is a valuable option in the management of dry eye disease according to an open-label study evaluating patients who previously used an artificial tear product. 2008-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292008/530334null XML http://www.modernmedicine.com/modernmedicine/Dry+Eye/Adding-artificial-tear-to-regimen-may-boost-effect/ArticleStandard/Article/detail/530336?contextCategoryId=417&ref=25 Cyclosporine A ophthalmic emulsion 0.05% (Restasis, Allergan) is effective in treating moderate to severe dry eye in 70% to 75% of patients with the condition, and adding a specific artificial tear (Systane, Alcon Laboratories) to the treatment regimen may prove beneficial for many other patients. 2008-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292008/530336null XML http://www.modernmedicine.com/modernmedicine/Dry+Eye/Crossover-study-results-favor-topical-corticostero/ArticleStandard/Article/detail/530340?contextCategoryId=417&ref=25 Loteprednol etabonate ophthalmic suspension 0.2% and olopatadine HCl ophthalmic solution 0.1% were compared in a study for the treatment of allergic conjunctivitis. After 14 days of use, the topical corticosteroid demonstrated greater efficacy in improving Ocular Surface Disease Index scores and was preferred by a significantly higher proportion of patients. Both medications were safe and well tolerated, and both led to improved signs and symptoms. 2008-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292008/530340null XML http://www.modernmedicine.com/modernmedicine/Dry+Eye/Sustained-release-insert-has-multitude-of-applicat/ArticleStandard/Article/detail/530342?contextCategoryId=417&ref=25 A hydroxypropyl cellulose ophthalmic insert (Lacrisert, Aton Pharma), a once-daily, preservative-free insert that helps to retain moisture, stabilize the tear film, lubricate the eye, and increase tear break-up time, may be beneficial in the treatment of patients with dry eye due to lid function abnormalities, closure problems, or thyroid disease. 2008-07-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/292008/530342null XML http://www.modernmedicine.com/modernmedicine/Cornea/Levofloxacin-15-safe-for-corneal-endothelium/ArticleStandard/Article/detail/522105?contextCategoryId=417&ref=25 Levofloxacin ophthalmic solution 1.5% (Iquix, Vistakon Pharmaceuticals), used to treat bacterial keratitis, has no adverse effects on the corneal endothelium after 2 weeks of intensive dosing for a total of 224 doses of the drug. 2008-06-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/232008/522105null XML http://www.modernmedicine.com/modernmedicine/Cornea/New-artificial-cornea-research-could-promise-incre/ArticleStandard/Article/detail/519446?contextCategoryId=417&ref=25 In an effort to make corneal transplants more available, researchers have designed an artificial cornea made from a water-filled polymer that resembles the eye's natural cornea. 2008-05-28T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/222008/519446null HTML http://www.modernmedicine.com/modernmedicine/Clinical+News/TB4-can-protect-cornea-against-oxidative-damage/ArticleStandard/Article/detail/518122?contextCategoryId=417&ref=25 Administering TB4 (Thymosin Beta 4, RegeneRx) up-regulates anti-oxidative enzymes in human corneal epithelial cells, helping to protect the cornea and resist oxidative damage, according to researchers. 2008-05-20T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/212008/518122null HTML http://www.modernmedicine.com/modernmedicine/Cornea/New-tear-formulation-provides-additional-option-fo/ArticleStandard/Article/detail/516484?contextCategoryId=417&ref=25 Carboxymethylcellulose 0.5% with compatible solutes (CMC-solutes) (Optive, Allergan), a new artificial tear formulation, when used with topical cyclosporine 0.05% (Restasis, Allergan) in patients with ocular surface disease, improved the objective signs and subjective symptoms of the disease when compared with the patients' previously used artificial tears. 2008-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/202008/516484null XML http://www.modernmedicine.com/modernmedicine/Cornea/Testing-platform-yields-point-of-care-osmolarity-m/ArticleStandard/Article/detail/516489?contextCategoryId=417&ref=25 A tear-testing platform under development could revolutionize osmolarity testing by making it possible to conduct tests quickly and accurately in the practice setting using a small volume of tears. 2008-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/202008/516489null XML http://www.modernmedicine.com/modernmedicine/Cornea/Loteprednol-etabonate-provides-multiple-benefits-f/ArticleStandard/Article/detail/516486?contextCategoryId=417&ref=25 When initiating treatment with topical cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan), adjunctive use of loteprednol etabonate ophthalmic suspension 0.5% (Lotemax, Bausch & Lomb) hastens and increases relief of dry eye signs and symptoms and reduces cyclosporine-associated burning and stinging without adding safety concerns, according to the results of a multicenter, randomized, controlled, masked trial comparing the combination regimen with cyclosporine plus artificial tears. 2008-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/202008/516486null XML http://www.modernmedicine.com/modernmedicine/Industry+News/UV-rays-dont-just-damage-skin/ArticleStandard/Article/detail/513870?contextCategoryId=417&ref=25 Prevent Blindness has dedicated May as UV Awareness Month in an effort to educate the public on the best way to protect their eyes. 2008-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/182008/513870null HTML http://www.modernmedicine.com/modernmedicine/Cornea/Cyclosporine-beneficial-for-treating-patients-with/ArticleStandard/Article/detail/516488?contextCategoryId=417&ref=25 Cyclosporine 0.05% ophthalmic emulsion (Restasis, Allergan) is beneficial for treating patients with dry eye because it increases goblet cell density and production of transforming growth factor ?2, an immunoregulatory factor, compared with artificial tear formulations, which do not. 2008-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/202008/516488null XML http://www.modernmedicine.com/modernmedicine/Cornea/Eye-drops-restore-and-maintain-ocular-surface-heal/ArticleStandard/Article/detail/516485?contextCategoryId=417&ref=25 Multiple studies evaluating the effects of treatment with Systane Lubricant Eye Drops (Alcon Laboratories) on corneal staining in patients with dry eye disease demonstrate this novel artificial tear has benefits for improving ocular surface health. 2008-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/202008/516485null XML http://www.modernmedicine.com/modernmedicine/Cornea/Once-daily-insert-designed-to-provide-lasting-dry-/ArticleStandard/Article/detail/516487?contextCategoryId=417&ref=25 A hydroxypropyl cellulose ophthalmic insert (Lacrisert, Aton Pharma) is a preservative-free product recommended for once-daily insertion in the inferior cul-de-sac. Its convenience, efficacy, and safety make it a valuable option for the management of dry eye disease. 2008-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/202008/516487null XML http://www.modernmedicine.com/modernmedicine/Cornea/Nanoparticle-offers-promise-for-treating-glaucoma/ArticleStandard/Article/detail/516482?contextCategoryId=417&ref=25 A cerium oxide nanoparticle bound to a human carbonic anhydrase inhibitor (hCAII) has shown promise as a drug-delivery device for treating glaucoma. In a series of experiments, investigators attached hCAII to the nanoparticle and also attached a fluorophore so that they could confirm the attachment and track the particle's inhibitory effects. 2008-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/202008/516482null XML http://www.modernmedicine.com/modernmedicine/Clinical+News/Old-and-young-cornea-donor-tissue-equally-effectiv/ArticleStandard/Article/detail/509405?contextCategoryId=417&ref=25 University of Rochester researchers recently put to test the bias against corneas from older donors. 2008-04-10T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152008/509405null HTML http://www.modernmedicine.com/modernmedicine/Cornea/Deep-anterior-lamellar-keratoplasty-yields-satisfa/ArticleStandard/Article/detail/506542?contextCategoryId=417&ref=25 Deep anterior lamellar keratoplasty resulted in satisfactory best spectacle-corrected visual acuity levels after 18 months follow-up. The rate of graft clarity was almost 90% and the rate of stromal rejection was low. However, the rate of endothelial cell loss at 18 months postoperatively was high. 2008-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142008/506542null XML http://www.modernmedicine.com/modernmedicine/Industry+News/Corneal-implants-okayed-for-use-in-Canada/ArticleStandard/Article/detail/506488?contextCategoryId=417&ref=25 Addition Technology has received regulatory clearance from Health Canada to market its corneal implants (Intacs) for keratoconus and myopia indications. 2008-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/142008/506488null XML http://www.modernmedicine.com/modernmedicine/Cornea/Calculating-corneal-SA-can-influence-IOL-selection/ArticleStandard/Article/detail/503972?contextCategoryId=417&ref=25 Calculating corneal spherical aberration—especially in eyes with extreme ranges of corneal spherical wavefront aberrations—by using the recorder function of a diagnostic system with analytical software may be beneficial when choosing an IOL that has positive, neutral, or negative SA to reduce postoperative SA in the whole eye. 2008-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/122008/503972null XML http://www.modernmedicine.com/modernmedicine/Cornea/SF6-associated-with-good-results-after-DSEK/ArticleStandard/Article/detail/504003?contextCategoryId=417&ref=25 Sutureless Descemet's stripping with endothelial keratoplasty may be a reliable method of endothelial keratoplasty with the use of sulfur hexafluoride in place of filtered air. 2008-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/122008/504003null XML http://www.modernmedicine.com/modernmedicine/Cornea/Olopatadine-beneficial-for-perennial-allergic-conj/ArticleStandard/Article/detail/498982?contextCategoryId=417&ref=25 A pooled analysis of three randomized, double-masked, placebo-controlled, conjunctival allergen challenge trials demonstrates that once-daily treatment with olopatadine 0.2% (Pataday, Alcon Laboratories) is equally effective for improving ocular itching caused by exposure to indoor or outdoor allergens. 2008-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/092008/498982null XML http://www.modernmedicine.com/modernmedicine/Cornea/Donor-endothelial-cell-counts-do-not-determine-dis/ArticleStandard/Article/detail/498988?contextCategoryId=417&ref=25 Preoperative donor endothelial cell count does not affect the rate of dislocation in endothelial keratoplasty. The surgical technique is likely the most important factor that drives the dislocation rate, primary graft failure rate, and long-term endothelial survival, according to one surgeon. 2008-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/092008/498988null XML http://www.modernmedicine.com/modernmedicine/Cornea/Pivotal-trial-results-for-vernal-conjunctivitis-dr/ArticleStandard/Article/detail/498983?contextCategoryId=417&ref=25 Results of a pivotal phase III trial of a cyclosporine A product for the treatment of vernal conjunctivitis (VKC) in children showed that the drug improved symptoms and signs of the orphan disease, and tolerability was excellent, according to the manufacturer. 2008-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/092008/498983null XML http://www.modernmedicine.com/modernmedicine/Cornea/Ocular-itching-drugs-are-numerous-in-the-pipeline/ArticleStandard/Article/detail/498980?contextCategoryId=417&ref=25 To treat the ocular discomfort associated with allergic conjunctivitis several medications are in the pipeline. 2008-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/092008/498980null XML http://www.modernmedicine.com/modernmedicine/Cornea/Absence-of-drying-effect-makes-epinastine-a-treatm/ArticleStandard/Article/detail/498981?contextCategoryId=417&ref=25 Epinastine HCl 0.05% does not have a drying effect on the ocular surface and may be kinder to patients being treated for seasonal allergies and underlying dry eye disease. 2008-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/092008/498981null XML http://www.modernmedicine.com/modernmedicine/Cornea/Study-evaluates-biological-integrity-of-corneal-ep/ArticleStandard/Article/detail/490637?contextCategoryId=417&ref=25 The use of chilled water and 0.1% hyaluronic acid during epi-LASIK improved the survival rate of corneal epithelial basal cells, according to one study. 2008-02-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/072008/490637null XML http://www.modernmedicine.com/modernmedicine/Cornea/Improved-vision-is-possible-for-children-with-mild/ArticleStandard/Article/detail/481002?contextCategoryId=417&ref=25 A better visual outcome can be achieved after corneal transplantation surgery in pediatric patients with Peters' anomaly type 1 if the surgery is performed when the patients are aged approximately 10 to 15 weeks and if the glaucoma and astigmatism are well controlled. 2007-12-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/522007/481002null XML http://www.modernmedicine.com/modernmedicine/Cornea/Donor-cornea-tissue-could-be-used-for-more-than-1-/ArticleStandard/Article/detail/470770?contextCategoryId=417&ref=25 The development of customized component corneal transplantation techniques could enable a single donor cornea to be used to treat multiple patients. The practice could help address tissue shortages and reduce the wait time for surgery in developing countries. A researcher formerly practicing in India talks about the first published report of this strategy. 2007-11-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/452007/470770null XML http://www.modernmedicine.com/modernmedicine/Cornea/Broad-spectrum-activity-of-antifungals-needs-furth/ArticleStandard/Article/detail/467240?contextCategoryId=417&ref=25 Findings of a study evaluating in vitro susceptibility of clinical fungal keratitis isolates suggest that use of newer antifungal medications may afford better outcomes in these potentially sight-threatening infections 2007-10-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/432007/467240null XML http://www.modernmedicine.com/modernmedicine/Cornea/CCT-inversely-related-to-risk-of-glaucoma-developm/ArticleStandard/Article/detail/467241?contextCategoryId=417&ref=25 Central corneal thickness (CCT) bears an inverse relationship with the risk of developing glaucoma. The risk of glaucoma progression, however, seems to be independent of CCT. New tonometry technology will allow for more accurate risk stratification of patients. 2007-10-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/432007/467241null XML http://www.modernmedicine.com/modernmedicine/Cornea/Artificial-cornea-holds-promise-for-high-risk-eyes/ArticleStandard/Article/detail/465538?contextCategoryId=417&ref=25 Several situations are associated with a high risk of failure after donor corneal transplantation. Encouraging results have been seen with a particular keratoprosthesis (Boston KPro, Massachusetts Eye and Ear Infirmary) as an alternative in carefully selected eyes. 2007-10-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/422007/465538null XML http://www.modernmedicine.com/modernmedicine/Cornea/Ophthalmic-NSAIDs-vary-in-amount-time-needed-to-re/ArticleStandard/Article/detail/459899?contextCategoryId=417&ref=25 Topical ophthalmic nonsteroidal anti-inflammatory drugs vary considerably in characteristics such as the number of days and the number of drops needed to reach the therapeutic endpoint. Although all are effective, doctors should learn to compare the NSAIDs based on their potency and penetration to make the best decisions for their patients. 2007-09-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/392007/459899null XML http://www.modernmedicine.com/modernmedicine/Cornea/Speed-of-kill-plays-vital-role-in-clinical-practic/ArticleStandard/Article/detail/459903?contextCategoryId=417&ref=25 The therapeutic regimen chosen by a clinician can have a major effect on surgical success, practice, and patient well-being. Here are the attributes you should look for. 2007-09-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/392007/459903null XML http://www.modernmedicine.com/modernmedicine/Cornea/Caution-urged-for-nepafenac-use-for-pain-control-a/ArticleStandard/Article/detail/459900?contextCategoryId=417&ref=25 A prospective, randomized, contralateral eye-controlled study demonstrated that eyes treated with nepafenac 0.1% (Nevanac, Alcon Laboratories) for 4 to 5 days after PRK had significantly greater haze than eyes treated with ketorolac tromethamine 0.4% (Acular LS, Allergan). The study findings and similar experience of other surgeons raise questions about the safety of nepafenac use after surface ablation procedures. 2007-09-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/392007/459900null XML